A Real-World Study of Bispecific Antibodies in Multiple Myeloma

Conditions: Multiple Myeloma Interventions: Other: Treated by bispecific antibodies, teclistamab or elranatamab in usual care; Other: Not treated by bispecific antibodies in usual care Sponsors: Assistance Publique - H ôpitaux de Paris Completed

Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials